The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Mark S. Sulkowski

Johns Hopkins University School of Medicine

600 North Wolfe Street

1830 Building

Room 448

USA

[email]@jhmi.edu

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Johns Hopkins University School of Medicine, 600 North Wolfe Street, 1830 Building, Room 448, USA. 2007
  • Department of Medicine, Division of Infectious Disease, Johns Hopkins University School of Medicine, Baltimore, USA. 2000 - 2007
  • Division of Infectious Diseases, Johns Hopkins Medical Institutions, 1830 East Monument Street, Room 319, USA. 2001 - 2006
  • Johns Hopkins Medical Institutions, Baltimore, Maryland 21287, USA. 2003
  • Center for Viral Hepatitis, Johns Hopkins University, Baltimore, Maryland 21205, USA. 2003

References

  1. Specific targeted antiviral therapy for hepatitis C. Sulkowski, M.S. Curr. Gastroenterol. Rep (2007) [Pubmed]
  2. Therapeutic issues in HIV/HCV-coinfected patients. Sulkowski, M.S., Benhamou, Y. J. Viral Hepat. (2007) [Pubmed]
  3. The HIV-coinfected patient: managing viral hepatitis. Sulkowski, M.S. J. Acquir. Immune Defic. Syndr. (2007) [Pubmed]
  4. Treatment algorithm for the management of hepatitis C in HIV-coinfected persons. Sulkowski, M.S. J. Hepatol. (2006) [Pubmed]
  5. Peginterferon alfa-2a does not alter the pharmacokinetics of methadone in patients with chronic hepatitis C undergoing methadone maintenance therapy. Sulkowski, M., Wright, T., Rossi, S., Arora, S., Lamb, M., Wang, K., Gries, J.M., Yalamanchili, S. Clin. Pharmacol. Ther. (2005) [Pubmed]
  6. Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus. Sulkowski, M.S., Mehta, S.H., Torbenson, M., Afdhal, N.H., Mirel, L., Moore, R.D., Thomas, D.L. AIDS (2005) [Pubmed]
  7. Management of the hematologic complications of hepatitis C therapy. Sulkowski, M.S. Clin. Liver. Dis (2005) [Pubmed]
  8. Perspectives on HIV/hepatitis C virus co-infection, illicit drug use and mental illness. Sulkowski, M.S., Thomas, D.L. AIDS (2005) [Pubmed]
  9. Therapy insight: Management of hepatitis C in patients coinfected with HIV. Sulkowski, M.S. Nature Clinical Practice. Gastroenterology & Hepatology (2005) [Pubmed]
  10. Drug-induced liver injury associated with antiretroviral therapy that includes HIV-1 protease inhibitors. Sulkowski, M.S. Clin. Infect. Dis. (2004) [Pubmed]
  11. Daily versus thrice-weekly interferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected persons: a multicenter randomized controlled trial. Sulkowski, M.S., Felizarta, F., Smith, C., Slim, J., Berggren, R., Goodman, R., Ball, L., Khalili, M., Dieterich, D.T. J. Acquir. Immune Defic. Syndr. (2004) [Pubmed]
  12. Changes in haemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infection. Sulkowski, M.S., Wasserman, R., Brooks, L., Ball, L., Gish, R. J. Viral Hepat. (2004) [Pubmed]
  13. Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir. Sulkowski, M.S., Mehta, S.H., Chaisson, R.E., Thomas, D.L., Moore, R.D. AIDS (2004) [Pubmed]
  14. Hepatitis C virus infection in HIV-infected patients. Sulkowski, M.S. Current. Hiv/aids. Reports (2004) [Pubmed]
  15. Hepatotoxicity associated with antiretroviral therapy containing HIV-1 protease inhibitors. Sulkowski, M.S. Semin. Liver Dis. (2003) [Pubmed]
  16. Anemia in the treatment of hepatitis C virus infection. Sulkowski, M.S. Clin. Infect. Dis. (2003) [Pubmed]
  17. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Sulkowski, M.S., Thomas, D.L., Mehta, S.H., Chaisson, R.E., Moore, R.D. Hepatology (2002) [Pubmed]
  18. Peginterferon-alpha-2a (40kD) and ribavirin in patients with chronic hepatitis C: a phase II open-label study. Sulkowski, M., Reindollar, R., Thomas, D.L., Brinkley-Laughton, S., Hudson, M., Yu, J. BioDrugs (2002) [Pubmed]
  19. Hepatitis C and progression of HIV disease. Sulkowski, M.S., Moore, R.D., Mehta, S.H., Chaisson, R.E., Thomas, D.L. JAMA (2002) [Pubmed]
  20. Hepatitis C Virus Infection in HIV-infected Patients. Sulkowski, M.S. Curr. Infect. Dis. Rep (2001) [Pubmed]
  21. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. Sulkowski, M.S., Thomas, D.L., Chaisson, R.E., Moore, R.D. JAMA (2000) [Pubmed]
  22. Hepatitis C virus infection as an opportunistic disease in persons infected with human immunodeficiency virus. Sulkowski, M.S., Mast, E.E., Seeff, L.B., Thomas, D.L. Clin. Infect. Dis. (2000) [Pubmed]
 
WikiGenes - Universities